Name: 글로벌 시장 동향
SKU: PH7428
Availability: InStock

보고서 요약(국문)

개요
전 세계 야맹증 치료 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
야맹증은 유전적 및 후천적 질환을 포함한 여러 원인에 의해 발생할 수 있습니다. 백내장, 근시, 녹내장과 같이 어두운 환경에서 시야가 흐려지고 악화되는 질환은 진정한 야맹증과 구별해야 합니다. 야맹증은 눈이 어두운 환경에 적응하지 못하는 상태를 말합니다. 간상세포의 문제가 야맹증의 가장 흔한 원인이지만, 그 외에도 여러 가지 원인이 있습니다.
야맹증의 정확한 치료 방법은 근본적인 원인에 따라 결정됩니다. 망막 간상세포의 노화는 여러 질환에 의해 발생합니다. 야맹증은 이러한 질환의 다른 이름입니다. 눈 통증, 메스꺼움, 시야 흐림, 빛 번짐, 빛 민감성, 원거리 시력 문제, 두통은 모두 이 질환의 증상입니다.
시장 동향: 성장 동인 및 제약 요인
근시 및 비타민 A 결핍증의 증가
근시와 비타민 A 결핍증은 점점 더 흔해지고 있는 두 가지 질환이며, 이러한 추세는 시장 성장의 주요 요인이 될 것입니다. 예를 들어, 국제 근시 연구소(International Myopia Institute)는 전 세계적으로 근시 유병률이 증가하고 있으며, 주로 생활 습관 요인으로 인해 2050년에는 세계 인구의 50%에 영향을 미칠 것으로 예상했습니다.
녹내장, 백내장, 망막 박리와 같은 시력 손상 질환의 위험 또한 근시와 관련이 있습니다. 또한, 세계보건기구(WHO)는 매년 비타민 A 결핍 아동 25만~50만 명이 실명하고, 그중 절반이 시력 상실 후 1년 이내에 사망한다고 추정합니다. 비타민 A 결핍은 예방 가능한 소아 실명의 가장 큰 원인이며, 흔한 소아 질환으로 인한 상당한 이환율과 사망률과 관련이 있습니다.
의료비 상승 또한 야맹증 치료 시장 성장률에 영향을 미치는 주요 요인입니다. 야맹증 치료 시장은 민간 및 공공 기관의 인식 제고 노력 증가와 정부 지원 확대, 그리고 의료 기술 발전으로 인해 성장할 것으로 예상됩니다.
시장 동향: 제약 요인
야맹증 치료의 효과는 여러 제약 요인에 의해 저해될 수 있습니다. 예를 들어, 야맹증 치료, 특히 수술 및 기타 전문적인 시술 비용은 재정적 여유가 없거나 건강 보험이 없는 사람들에게 필수적인 치료를 받기 어렵게 만들 수 있습니다.
또한, 질환을 효과적으로 관리하고 치료하기 위해서는 조기 진단이 필수적입니다. 안과 분야, 특히 희귀하거나 유전적인 원인의 야맹증에 대한 연구 개발 부족은 발전된 치료 옵션의 이용 가능성을 제한할 수 있습니다. 근본 원인 파악이 지연되면 치료 선택지가 제한되고 치료 효과가 떨어질 수 있습니다.
세분화 분석
전 세계 야맹증 치료 시장은 치료 유형, 연령대, 진단, 판매 채널 및 지역별로 세분화됩니다.
유형별 세그먼트 중 유전자 치료 세그먼트는 야맹증 치료 시장 점유율의 약 40.7%를 차지했습니다.
특정 유전적 이상으로 발생하는 야맹증과 같은 다양한 유전 질환을 치료하는 유망한 접근법 중 하나는 유전자 치료입니다. 야맹증(Nyctalopia)은 망막 세포, 특히 저조도 시각을 담당하는 간상 세포의 기능에 중요한 유전자 변이와 관련이 있는 경우가 많습니다. 연구자들은 돌연변이 유전자의 기능을 향상시키거나 결함이 있는 유전자를 대체할 수 있는 치료 유전자를 개발합니다(유전자 대체 요법). 이 유전자는 종종 망막의 광수용체 세포 기능을 개선하여 야맹증을 치료하기 위해 개발됩니다.
예를 들어, 2021년 3월 Elsevier Inc.에 따르면, 한 연구에서 유전자 치료가 CSNB(선천성 야맹증)를 앓는 성인 쥐의 야간 시력을 크게 향상시킬 수 있음을 보여주었습니다. 이와 유사하게, 일부 유형의 CSNB는 망막의 신경 세포를 표적으로 하는 특수 유전자 치료를 통해 치료될 수 있습니다. 현재 CSNB에 대한 치료법은 없지만, 최근 유전자 치료의 발전은 가능성을 제시하고 있습니다. 이 질환을 관리하기 위해서는 전반적인 삶의 질과 야간 시력을 향상시키는 것이 종종 필요합니다.
지역 분석
북미는 2022년 시장 점유율의 약 36.4%를 차지했습니다.
북미는 주요 기업들의 존재, 높은 가처분 소득, 그리고 잘 구축된 의료 인프라 덕분에 야맹증 치료 시장을 주도하고 있습니다. 또한, 당뇨병, 녹내장, 백내장의 유병률이 증가하고 있으며, 정부 및 민간 기관의 인식 제고 노력이 강화됨에 따라 이 지역의 야맹증 치료 시장이 확대될 것으로 예상됩니다.
예를 들어, 당뇨병 연구소 재단(Diabetes Research Institute Foundation)에 따르면, 미국 인구의 약 11.3%에 해당하는 3,730만 명이 당뇨병을 앓고 있으며, 약 2,900만 명이 당뇨병 진단을 받았습니다. 약 850만 명이 당뇨병을 앓고 있지만 아직 진단을 받지 못했습니다.
또한 BrightFocus Foundation의 2023년 자료에 따르면, 300만 명 이상의 미국인이 녹내장을 앓고 있으며, 그중 270만 명(40세 이상)은 가장 흔한 형태인 개방각 녹내장을 앓고 있습니다. 따라서 위의 요인들이 해당 지역의 성장을 가속화합니다.
COVID-19 영향 분석
일부 안과 시술 및 선택적 수술과 같은 많은 비응급 의료 서비스는 COVID-19 환자에게 자원을 우선적으로 제공하기 위해 전염병이 절정에 달했을 때 연기되거나 취소되었습니다. 이러한 합병증으로 인해 야맹증 치료를 쉽게 받을 수 없었을 수 있습니다. 병원 및 의료 시설은 COVID-19 환자를 우선시해야 할 수 있으며, 이로 인해 일부 안과 관련 시술과 같은 덜 긴급한 치료가 지연될 수 있습니다.
야맹증 관련 수술의 일정 및 접근성은 이러한 우선순위 변경의 영향을 받을 수 있습니다. 코로나19 팬데믹으로 인한 경제적 영향, 즉 많은 사람들의 실직과 소득 감소는 야맹증 치료를 포함한 의료 서비스 비용을 지불하는 것을 더욱 어렵게 만들 수 있습니다. 재정적 제약으로 인해 절대적으로 필요하지 않은 의료 수술은 연기되거나 아예 받지 못하게 될 수도 있습니다.
시장 세분화
치료 유형별
• 약물 치료
• 유전자 치료
• 기타
연령대별
• 소아
• 성인
진단별
• 혈액 검사
• 색각 검사
• 망막전위도(ERG)
• 기타
판매 채널별
• 유통 채널
• 최종 사용자
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Nestle, NOWfoods Inc, Kirkland Signature, Life Extension, Garden of Life, Nidek, Inc, Alcon Laboratories, Inc, Carl Zeiss, Inc, VISX, Inc, Wavelight AG 등이 있습니다.

주요 동향
• 2022년 7월 21일, BASF는 루트비히스하펜에 위치한 통합 공장의 글로벌 제형 역량을 강화함으로써 비타민 A 시장에서의 입지를 공고히 했습니다. 이 혁신적인 시설은 해당 지역의 비타민 생산에 완전히 통합되어 동물 영양 산업을 위한 고품질 비타민 A 분말 제품 생산을 지원하고 확대할 것입니다.

• 2023년 8월 7일, 후이다진(HuidaGene)은 전임상 연구에서 자사의 유전자 치료 후보 물질이 FDA 승인 의약품인 룩스터나(Luxturna)를 능가하는 결과를 보였습니다. 중국에 본사를 둔 후이다진의 HG004라는 일회성 유전자 대체 요법은 RPE65 유전자 변이로 인한 유전성 망막 질환(IRD) 환자 치료를 위해 개발되었으며, 2023년 3월에 희귀 의약품 지정을 받았습니다.

보고서 구매 이유:

• 치료 유형, 연령대, 진단, 판매 채널 및 지역별 글로벌 야맹증 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 야맹증 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 야맹증 치료 시장 보고서는 약 69개의 표, 66개의 그림, 187페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Night Blindness Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Night blindness can be caused by many disease processes, both inherited and acquired. Differentials that may cause blurred vision, and that are made worse by low light levels (e.g., cataracts, myopia, glaucoma) should be distinguished from true night blindness. The inability of the eyes to adjust to dim lighting conditions is known as night blindness. Although issues with the rod cells are the most frequent cause of night blindness, there are numerous additional causes as well.
The underlying cause determines the exact procedure for treatment for night blindness. The ageing of the retina's rods is brought on by a number of diseases. Nyctalopia is another name for disease. Eye pain, nausea, blurred vision, halos, light sensitivity, distance vision problem, and headaches are all symptoms of this diseases.
Market Dynamics: Drivers and Restraints
The rising prevalence of myopia and vitamin A deficiency
The rise of myopia and vitamin A deficiency are two conditions that are becoming more common, and this development will be a key factor in the market's advancement. For instance, The International Myopia Institute reported that the prevalence of myopia is rising globally and is expected to impact 50% of the world's population by 2050, primarily as a result of lifestyle factors.
The risk of sight-threatening disorders from glaucoma, cataract, and retinal detachment has also been linked to myopia. Additionally, WHO estimates that every year, between 250,000 and 500,000 children who are vitamin A deficient become blind, and half of them pass away within a year after losing their sight. Vitamin A deficiency is the largest preventable cause of childhood blindness and is related with considerable morbidity and mortality from common childhood illnesses.
The rising cost of healthcare is also a major factor affecting the market's growth rate for treatments for night blindness. The market for night blindness treatments will grow as a result of rising awareness-raising efforts by private as well as public organisations and increasing government support, in addition to developments in medical technology.
Market Dynamics: Restraint
The effectiveness of therapies can be hampered by a number of restraints on the management of night blindness. For instance, the cost of treating night blindness, particularly through surgeries and other specialised interventions, might make it difficult for those without sufficient financial means or health insurance to get the essential care.
Additionally, an immediate diagnosis is essential for managing and treating the condition effectively. Lack of extensive research and development in some areas of ophthalmology, particularly for rare or genetic causes of night blindness, can also limit the availability of advanced treatment options. Delay in identifying the underlying cause can also restrict treatment options and reduce the effectiveness of interventions.
Segment Analysis
The global night blindness treatment marketis segmented based on treatment type, age group, diagnosis, sales channel and region.
The gene therapy segment from the type segment accounted for approximately 40.7% of night blindness treatment share
A promising approach for treating a variety of genetic diseases, such as night blindness caused on by particular genetic abnormalities, is gene therapy. Nyctalopia, often known as night blindness, is frequently linked to gene variations that are crucial for the operation of retinal cells, particularly rod cells, which are responsible for seeing in low light. Researchers create a therapeutic gene that can either enhance the function of the mutant gene or replace the defective gene (gene replacement therapy). This gene is often created to improve the function of photoreceptor cells in the retina to treat night blindness.
For instance, in March 2021, according to Elsevier Inc, a study demonstrates that gene therapy can significantly improve night vision in adult mice with CSNB. Similar to this, some types of CSNB can be cured by using a special type of gene therapy that targets the nerve cells in the retina. While there is presently no treatment for CSNB, recent developments in gene therapy provide opportunity. Adaptations to enhance general quality of life and night vision are frequently necessary for managing this disease.
Geographical Analysis
North America accounted for approximately 36.4% of the market share in 2022
Due to the existence of significant key players, high disposable income, and well-established healthcare infrastructure in North America, this region dominates the market for night blindness treatments. Additionally, the prevalence of diabetes, glaucoma, and cataract will rise, along with increased attempts by governmental and commercial organisations to raise awareness. These factors will lead to an expansion of the night blindness treatment market in the region.
For instance, according to Diabetes Research Institute Foundation, around 37.3 million people, or 11.3% of the U.S. population, have diabetes. An estimated 29 million people – had diagnosed diabetes. Approximately 8.5 million people have diabetes but have not yet been diagnosed.
Additionally, according to BrightFocus Foundation 2023, more than 3 million Americans are living with glaucoma, 2.7 million of whom (aged 40 and older) are affected by its most common form, open-angle glaucoma.Thus above factors accelerates the region growth.
COVID-19 Impact Analysis
Many non-emergency medical services, such as some eye care procedures and elective operations, were postponed or cancelled during the peak of the epidemic in order to prioritize resources for COVID-19 patients. Treatments for night blindness may not have been as readily available because of this complication. Hospitals and healthcare facilities may need to give COVID-19 patients priority, which could cause delays for less urgent treatments, such as some ophthalmology-related procedures.
The scheduling and accessibility of operations linked to night blindness may be impacted by this reprioritization. The pandemic's economic effects, which include job losses and decreased income for many people, may make it more difficult for them to pay for healthcare services, including treatments for night blindness. Medical operations that are not absolutely necessary may be postponed or avoided due to financial restrictions.
Market Segmentation
By Treatment Type
• Medication
• Gene Therapy
• Others
By Age Group
• Pediatric
• Adult
By Diagnosis
• Blood tests
• Color vision testing
• Electroretinogram (ERG)
• Others
By Sales Channel
• Distribution Channel
• End User
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Nestle, NOWfoods Inc, Kirkland Signature, Life Extension, Garden of Life, Nidek, Inc, Alcon Laboratories, Inc, Carl Zeiss, Inc, VISX, Inc, Wavelight AG and among others.
Key Developments
• On July 21, 2022, by increasing its global formulation capabilities at its Verbund plant in Ludwigshafen, BASF is enhancing its market position in the vitamin A market. The innovative facility, which is fully integrated into vitamin production at the location, will support and increase the manufacture of high-quality vitamin A powder products for the animal nutrition industry.
• On August 07, 2023, HuidaGene, in preclinical research, its gene therapy candidate exceeded FDA-approved Luxturna. One-time gene replacement therapy called HG004 by China-based HuidaGene, which was granted orphan drug status in March 2023, is designed to treat people with inherited retinal diseases (IRDs) brought on by mutations in the RPE65 gene.
Why Purchase the Report?
• To visualize the global night blindness treatment market segmentation based on treatment type, age group, diagnosis, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of night blindness treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global night blindness treatment market report would provide approximately 69 tables, 66 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Age Group
3.3. Snippet by Diagnosis
3.4. Snippet by Sales Channel
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising prevalence of myopia and vitamin A deficiency
4.1.1.2. Technological advancements of the treatment
4.2. Restraints
4.2.1.1. Expensive cost associated with the treatment
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Medication *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gene Therapy
7.4. Others
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatric *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adult
9. By Diagnosis
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
9.1.2. Market Attractiveness Index, By Diagnosis
9.2. Blood tests *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Color vision testing
9.4. Electroretinogram (ERG)
9.5. Others
10. By Sales Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.1.2. Market Attractiveness Index, By Sales Channel
10.2. Distribution Channel *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. End User
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Nestle *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. NOWfoods Inc
13.3. Kirkland Signature
13.4. Life Extension
13.5. Garden of Life
13.6. Nidek, Inc
13.7. Alcon Laboratories, Inc
13.8. Carl Zeiss, Inc
13.9. VISX, Inc
13.10. Wavelight AG
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Nestle, 4.	Key Developments, NOWfoods Inc, Kirkland Signature, Life Extension, Garden of Life, Nidek, Inc, Alcon Laboratories, Inc, Carl Zeiss, Inc, VISX, Inc, Wavelight AG

표 목록 (Tables)

List of Tables

Table 1 Global Night Blindness Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Night Blindness Treatment Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Night Blindness Treatment Market Value, By Diagnosis, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Night Blindness Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Night Blindness Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Night Blindness Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Night Blindness Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 8 Global Night Blindness Treatment Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Night Blindness Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 10 Global Night Blindness Treatment Market Value, By Diagnosis, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Night Blindness Treatment Market Value, By Diagnosis, 2021-2030 (US$ Million)

Table 12 Global Night Blindness Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Night Blindness Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 14 Global Night Blindness Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Night Blindness Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Night Blindness Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 17 North America Night Blindness Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 18 North America Night Blindness Treatment Market Value, By Diagnosis, 2021-2030 (US$ Million)

Table 19 North America Night Blindness Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 North America Night Blindness Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Night Blindness Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 22 South America Night Blindness Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 23 South America Night Blindness Treatment Market Value, By Diagnosis, 2021-2030 (US$ Million)

Table 24 South America Night Blindness Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 25 South America Night Blindness Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Night Blindness Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 27 Europe Night Blindness Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 28 Europe Night Blindness Treatment Market Value, By Diagnosis, 2021-2030 (US$ Million)

Table 29 Europe Night Blindness Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 30 Europe Night Blindness Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Night Blindness Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Night Blindness Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Night Blindness Treatment Market Value, By Diagnosis, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Night Blindness Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Night Blindness Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Night Blindness Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Night Blindness Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Night Blindness Treatment Market Value, By Diagnosis, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Night Blindness Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 40 Nestle: Overview

Table 41 Nestle: Product Portfolio

Table 42 Nestle: Key Developments

Table 43 NOWfoods Inc: Overview

Table 44 NOWfoods Inc: Product Portfolio

Table 45 NOWfoods Inc: Key Developments

Table 46 Kirkland Signature: Overview

Table 47 Kirkland Signature: Product Portfolio

Table 48 Kirkland Signature: Key Developments

Table 49 Life Extension: Overview

Table 50 Life Extension: Product Portfolio

Table 51 Life Extension: Key Developments

Table 52 Garden of Life: Overview

Table 53 Garden of Life: Product Portfolio

Table 54 Garden of Life: Key Developments

Table 55 Nidek, Inc: Overview

Table 56 Nidek, Inc: Product Portfolio

Table 57 Nidek, Inc: Key Developments

Table 58 Alcon Laboratories, Inc: Overview

Table 59 Alcon Laboratories, Inc: Product Portfolio

Table 60 Alcon Laboratories, Inc: Key Developments

Table 61 Carl Zeiss, Inc: Overview

Table 62 Carl Zeiss, Inc: Product Portfolio

Table 63 Carl Zeiss, Inc: Key Developments

Table 64 VISX, Inc: Overview

Table 65 VISX, Inc: Product Portfolio

Table 66 VISX, Inc: Key Developments

Table 67 Wavelight AG: Overview

Table 68 Wavelight AG: Product Portfolio

Table 69 Wavelight AG: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Night Blindness Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 3 Global Night Blindness Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 4 Global Night Blindness Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 5 Global Night Blindness Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 6 Global Night Blindness Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Night Blindness Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 8 Medication Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Gene Therapy Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Others Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Global Night Blindness Treatment Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 12 Pediatric Age Group in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Adult Age Group in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Global Night Blindness Treatment Market Y-o-Y Growth, By Diagnosis, 2022-2030 (%)

Figure 15 Blood tests Diagnosis in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Color vision testing Diagnosis in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Electroretinogram (ERG) Diagnosis in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Others Diagnosis in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Global Night Blindness Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 20 Distribution Channel Sales Channel in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 End User Sales Channel in Global Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Global Night Blindness Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 South America Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 North America Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 North America Night Blindness Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 30 North America Night Blindness Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 31 North America Night Blindness Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 32 North America Night Blindness Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 33 North America Night Blindness Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 35 South America Night Blindness Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 36 South America Night Blindness Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 37 South America Night Blindness Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 38 South America Night Blindness Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 39 South America Night Blindness Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Night Blindness Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 42 Europe Night Blindness Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 43 Europe Night Blindness Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 44 Europe Night Blindness Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 45 Europe Night Blindness Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 46 Asia-Pacific Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 47 Asia-Pacific Night Blindness Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 48 Asia-Pacific Night Blindness Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 49 Asia-Pacific Night Blindness Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 50 Asia-Pacific Night Blindness Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 51 Asia-Pacific Night Blindness Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 52 Middle East & Africa Night Blindness Treatment Market Value, 2021-2030 (US$ Million)

Figure 53 Middle East & Africa Night Blindness Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 54 Middle East & Africa Night Blindness Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 55 Middle East & Africa Night Blindness Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 56 Middle East & Africa Night Blindness Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 57 Nestle: Financials

Figure 58 NOWfoods Inc: Financials

Figure 59 Kirkland Signature: Financials

Figure 60 Life Extension: Financials

Figure 61 Garden of Life: Financials

Figure 62 Nidek, Inc: Financials

Figure 63 Alcon Laboratories, Inc: Financials

Figure 64 Carl Zeiss, Inc: Financials

Figure 65 VISX, Inc: Financials

Figure 66 Wavelight AG: Financials

세계 야맹증 치료 시장 – 2023-2030

Global Night Blindness Treatment Market - 2023-2030